← All Catalyst Pharmaceuticals, INC filings

Catalyst Pharmaceuticals, INC 8-K filings

NASDAQ
CPRX
Catalyst Pharmaceuticals, INC
8-K: Catalyst Pharmaceuticals Highlights Positive Long-Term Data for AGAMREE in Duchenne Muscular Dystrophy
Catalyst Pharmaceuticals announces the publication of Santhera's VISION-DMD study in Neurology, supporting the long-term efficacy and safety of AGAMREE (vamorolone) in treating Duchenne Muscular Dystrophy.